Although several studies [11-13] have compared the impact of these two second-generation basal insulin analogues on glycemic variability in patients with type 1diabetes mellitus (T1DM), there is little data and head-to-head comparison of IDeg-100 and IGlar-300 regarding their simultaneous impact on glycemic variability and oxidative stress in patients with T2DM. This evidence concerns the gene INS and diabetes mellitus.